RemeGen Co

RemeGen Co P/FCF

The P/FCF (Price-to-Free-Cash-Flow Ratio) of RemeGen Co (688331.SS) as of Oct 26, 2026 is -350.84. In the previous year, P/FCF (Price-to-Free-Cash-Flow Ratio) was -35.01 — a change of 902.17% (lower).

P/FCF

-350.84

YoY

902.17%

Last updated:

P/FCF (Price-to-Free-Cash-Flow Ratio) of RemeGen Co is 2025 -350.84 . P/FCF (Price-to-Free-Cash-Flow Ratio) of RemeGen Co was 2024 -35.01 . It decreases by 902.17% lower compared to the previous year.

The RemeGen Co P/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/FCF
Date
P/FCF
Jan 1, 2018
-238.27 CNY
Jan 1, 2019
-145.00 CNY
Jan 1, 2020
-44.22 CNY
Jan 1, 2021
-142.64 CNY
Jan 1, 2022
-24.96 CNY
Jan 1, 2023
-21.43 CNY
Jan 1, 2024
-35.01 CNY
Jan 1, 2025
-350.84 CNY
The RemeGen Co P/FCF history
YEARP/FCFYoY
-350.84+902.17%
-35.01+63.38%
-21.43-14.16%
-24.96-82.50%
-142.64+222.56%
-44.22-69.50%
-145.00-39.14%
-238.27—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

RemeGen Co Stock analysis

What does RemeGen Co do? RemeGen Co Ltd generates revenue by researching, developing, and manufacturing innovative biopharmaceuticals, specifically focusing on therapeutic antibody drugs. The company's product portfolio includes tetacept (RC18), veldicitumab (RC48), and a dual-target fusion protein (RC28). These products are designed to treat major diseases such as oncology, autoimmune diseases, and ophthalmology. The firm operates primarily in the domestic market within China, where it commercializes its discoveries. Its business model relies on the development of various antibody types, including antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies. This focus allows the company to address significant medical needs through its specialized therapeutic offerings. RemeGen Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about RemeGen Co stock

P/FCF (Price-to-Free-Cash-Flow Ratio) of RemeGen Co is -350.84 in 2025.

P/FCF (Price-to-Free-Cash-Flow Ratio) of RemeGen Co changed from -35.01 to -350.84, representing a 902.17% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/FCF (Price-to-Free-Cash-Flow Ratio) RemeGen Co since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Free-Cash-Flow ratio measures how much investors pay for each unit of free cash flow. A lower ratio may indicate better value.

P/FCF = Market Capitalization / Free Cash Flow

To evaluate P/FCF (Price-to-Free-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/FCF (Price-to-Free-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/FCF (Price-to-Free-Cash-Flow Ratio)'s RemeGen Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — RemeGen Co

All Key Metrics — RemeGen Co